These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 37598126)
41. AGER1 deficiency-triggered ferroptosis drives fibrosis progression in nonalcoholic steatohepatitis with type 2 diabetes mellitus. Gong Y; Liu Z; Zhang Y; Zhang J; Zheng Y; Wu Z Cell Death Discov; 2023 Jun; 9(1):178. PubMed ID: 37280194 [TBL] [Abstract][Full Text] [Related]
42. Epithelial-mesenchymal transition as a fundamental mechanism underlying the cancer phenotype. Cervantes-Arias A; Pang LY; Argyle DJ Vet Comp Oncol; 2013 Sep; 11(3):169-84. PubMed ID: 22404947 [TBL] [Abstract][Full Text] [Related]
43. Lipid Peroxidation and Iron Metabolism: Two Corner Stones in the Homeostasis Control of Ferroptosis. Rochette L; Dogon G; Rigal E; Zeller M; Cottin Y; Vergely C Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613888 [TBL] [Abstract][Full Text] [Related]
44. Ferroptosis-Driven Nanotherapeutics to Reverse Drug Resistance in Tumor Microenvironment. Zhu L; Meng D; Wang X; Chen X ACS Appl Bio Mater; 2022 Jun; 5(6):2481-2506. PubMed ID: 35614872 [TBL] [Abstract][Full Text] [Related]
45. Pharmacological Targeting of Epithelial-to-Mesenchymal Transition in Colorectal Cancer. Zafari N; Velayati M; Nassiri M; Khazaei M; Hassanian SM; Ferns GA; Avan A Curr Pharm Des; 2022; 28(28):2298-2311. PubMed ID: 35909286 [TBL] [Abstract][Full Text] [Related]
46. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Yang WS; Kim KJ; Gaschler MM; Patel M; Shchepinov MS; Stockwell BR Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E4966-75. PubMed ID: 27506793 [TBL] [Abstract][Full Text] [Related]
47. Metadherin enhances vulnerability of cancer cells to ferroptosis. Bi J; Yang S; Li L; Dai Q; Borcherding N; Wagner BA; Buettner GR; Spitz DR; Leslie KK; Zhang J; Meng X Cell Death Dis; 2019 Sep; 10(10):682. PubMed ID: 31527591 [TBL] [Abstract][Full Text] [Related]
48. Inhibition of ACSL4 attenuates ferroptotic damage after pulmonary ischemia-reperfusion. Xu Y; Li X; Cheng Y; Yang M; Wang R FASEB J; 2020 Dec; 34(12):16262-16275. PubMed ID: 33070393 [TBL] [Abstract][Full Text] [Related]
49. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463 [TBL] [Abstract][Full Text] [Related]
50. Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition. Malek R; Wang H; Taparra K; Tran PT Cells Tissues Organs; 2017; 203(2):114-127. PubMed ID: 28214899 [TBL] [Abstract][Full Text] [Related]
51. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. Giannelli G; Koudelkova P; Dituri F; Mikulits W J Hepatol; 2016 Oct; 65(4):798-808. PubMed ID: 27212245 [TBL] [Abstract][Full Text] [Related]
52. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Wu J; Minikes AM; Gao M; Bian H; Li Y; Stockwell BR; Chen ZN; Jiang X Nature; 2019 Aug; 572(7769):402-406. PubMed ID: 31341276 [TBL] [Abstract][Full Text] [Related]
53. Epithelial Mesenchymal Transition in Aggressive Lung Cancers. Mittal V Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798 [TBL] [Abstract][Full Text] [Related]
54. Role of GPX4 in ferroptosis and its pharmacological implication. Seibt TM; Proneth B; Conrad M Free Radic Biol Med; 2019 Mar; 133():144-152. PubMed ID: 30219704 [TBL] [Abstract][Full Text] [Related]
55. Targeting EMT in cancer: opportunities for pharmacological intervention. Davis FM; Stewart TA; Thompson EW; Monteith GR Trends Pharmacol Sci; 2014 Sep; 35(9):479-88. PubMed ID: 25042456 [TBL] [Abstract][Full Text] [Related]
56. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. Messeha SS; Zarmouh NO; Soliman KFA Nutrients; 2021 May; 13(5):. PubMed ID: 34069461 [TBL] [Abstract][Full Text] [Related]
57. Potent nanoreactor-mediated ferroptosis-based strategy for the reversal of cancer chemoresistance to Sorafenib. Wang X; Zhao L; Wang C; Wang L; Wu H; Song X; Wang W; Xu H; Dong X Acta Biomater; 2023 Mar; 159():237-246. PubMed ID: 36736851 [TBL] [Abstract][Full Text] [Related]
58. Understanding the mechanistic regulation of ferroptosis in cancer: the gene matters. Gao M; Fan K; Chen Y; Zhang G; Chen J; Zhang Y J Genet Genomics; 2022 Oct; 49(10):913-926. PubMed ID: 35697272 [TBL] [Abstract][Full Text] [Related]
59. Diverse pathways of epithelial mesenchymal transition related with cancer progression and metastasis and potential effects of endocrine disrupting chemicals on epithelial mesenchymal transition process. Lee HM; Hwang KA; Choi KC Mol Cell Endocrinol; 2017 Dec; 457():103-113. PubMed ID: 28042023 [TBL] [Abstract][Full Text] [Related]
60. miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer. Yu J; Xie F; Bao X; Chen W; Xu Q Mol Cancer; 2014 May; 13():121. PubMed ID: 24885626 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]